logo-loader
viewDirecta Plus PLC

Directa Plus confident of meeting full year expectations

Directa Plus is principally focussed on the two sectors in which it has a strong commercial advantage: environmental (based on its Grafysorber product) and textiles (based on its G+ products)

Target
The company is on course to meet full-year targets

Directa Plus Plc (AIM: DCTA) shares rose on Thursday after the producer and supplier of graphene-based products said it has made good progress in the second half of 2018.

In a brief trading update, the company said it was confident of achieving consensus market estimates for the full year, including revenues of €2.3mln.

READ: Directa Plus targets India as it extends partnership with textiles giant Arvind

"2018 has been a good year for Directa Plus, in terms of accelerating commercial traction, agreements and collaborations signed and orders for our products this year and 2019,” said Giulio Cesareo, the chief executive officer of Directa Plus.

“We also repositioned ourselves in the key verticals we target for G+ products in order to move up the value chain, selling more than just pristine graphene nanoplatelets, so as to capture additional value for our shareholders. Looking forward we now have clearer visibility of a proportion of next year's revenue, and as such the board looks forward to 2019 with increasing confidence," he added.

In mid-morning trading, Directa Plus shares were 3.3% higher at 47.50p.

 -- Adds share price --


 

Quick facts: Directa Plus PLC

Price: 75 GBX

AIM:DCTA
Market: AIM
Market Cap: £45.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Directa Plus PLC named herein, including the promotion by the Company of Directa Plus PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: DeepMatter to collaborate with AstraZeneca

Headlines from the Proactive UK newsroom. DeepMatter (LON:DMTR) has agreed a tie-up with AstraZeneca to combine their drug development technology platforms. Deepmatter uses AI to monitor and record chemical reactions during drug development. Rare disease database group Open Orphan...

on 9/12/19

2 min read